Clinical trial · Observational
Pilot Study for Evaluating the Role of F-18 FLT PET/CT in Therapeutic Decision Making in Non-small Cell Lung Cancer
The Role of F-18 FLT PET/CT for Selecting the Patients Who Need Maintenance Treatment After First-line Chemotherapy in Advanced Non-small Cell Lung Cancers
NCT01619241CI-TRIAL-00007186unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this pilot study is to determine whether 18F-FLT PET/CT can predict which patients will have poorer progression free survival and overall survival in advanced Non-small Cell Lung Cancer (NSCLC) after first-line therapy and, therefore, need more aggressive treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- advanced non-small cell lung cancer
- interventionNames
- Other: PET/CT
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- from the date of FLT PET/CT to the date of death or last follow-up, assessed up to 1 year
Secondary outcomes (1)
- measure
- time to progression
- timeFrame
- from the date of FLT PET/CT to the date of documented progression or last follow-up, assessed up to 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * advanced non-small cell lung cancer (stage IIIB, IV) * at least one measurable lesion * performance status (ECOG) 0-2 * 1st-line platinum chemotherapy and no progression Exclusion Criteria: * mixed small cell and non-small cell * uncontrolled brain metastasis * previous malignancy within 5 years (except basal cell carcinoma of skin, carcinoma in situ of uterine cervix) * pregnant or breast feeding * pemetrexed chemotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.